Pancreatic Cancer Precision Medicine Market (2025 - 2030) Size, Share & Trends Analysis Report By Therapeutic Approach (Targeted Therapy, Immunotherapy, Chemotherapy-precision Combinations), By Diagnostic Technology, By Region, And Segment Forecasts

Pancreatic Cancer Precision Medicine Market Summary

The global pancreatic cancer precision medicine market size was estimated at USD 656.9 million in 2024 and is projected to reach USD 1.88 billion by 2030, growing at a CAGR of 19.2% from 2025 to 2030. The adoption of targeted therapies and immunotherapies is on the rise, leading to enhanced survival rates and minimized side effects.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Key Market Troral appliancesends & Insights

• The North America dominated the global pancreatic cancer precision medicine market with a revenue share of 42.9% in 2024.
• The Asia Pacific pancreatic cancer precision medicine industry is expected to register the fastest CAGR of 6.1% in the forecast period.
• Based on therapeutic approach, the targeted therapy dominated the market and accounted for a share of 56.0% in 2024.
• Based on diagnostic technology, the genomic testing led the market and accounted for a share of 40.8% in 2024.

Market Size & Forecast

• 2024 Market Size: USD 656.9 Million
• 2030 Projected Market Size: USD 1.88 Billion
• CAGR (2025-2030): 19.2%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market

Advanced diagnostic tools, such as liquid biopsies and molecular profiling, are improving early detection and treatment efficacy. This shift towards precision medicine is a key driver of market growth, as it enables more effective treatment strategies tailored to individual patient profiles.

To learn more about this report, Download Free Sample Report

The integration of next-generation sequencing and bioinformatics is facilitating the discovery of new therapeutic targets, enabling more effective drug design. This technological progress is crucial in supporting the development of innovative therapies that can address the complex biology of pancreatic cancer. The rising investments from pharmaceutical companies, academic institutions, and government organizations are also essential for advancing research in this area. Initiatives such as the PanCAN grants program highlight the commitment to funding research in pancreatic cancer, further driving growth of the pancreatic cancer precision medicine industry.

The increasing incidence of pancreatic cancer, driven by lifestyle factors and an aging population, is creating a higher demand for specialized treatments. According to Cancer Australia, the estimated number of new pancreatic cancer cases diagnosed in 2024 was 4,641. This growing prevalence of the disease is propelling market growth, as patients and healthcare providers seek more effective and targeted treatment options. Strategic collaborations between pharmaceutical companies and research institutions are also fostering innovation and expanding the range of available therapies, further accelerating market growth.

Regulatory support is also a key driver of market growth, with strong governmental support through healthcare funding and initiatives aimed at early diagnosis and access to advanced therapies. This supportive environment enables the development and commercialization of new precision medicine treatments for pancreatic cancer.

Therapeutic Approach Insights

Targeted therapy dominated the market and accounted for a share of 56.0% in 2024. Advancements in personalized treatment and genomic profiling have led to targeted therapies that enhance efficacy and minimize side effects. Promising results from clinical trials involving PARP and immune checkpoint inhibitors, coupled with increased investment in research, drive demand. Governmental support and industry collaborations further facilitate the development and accessibility of these advanced treatments.

Chemotherapy-precision combinations is expected to grow at the fastest CAGR of 20.3% over the forecast period. The shift towards combining chemotherapy with precision medicine in pancreatic cancer has enhanced treatment efficacy by targeting specific molecular pathways. This approach helps overcome resistance to standard chemotherapy by integrating precision therapies tailored to individual genetic mutations. Ongoing clinical trials have demonstrated the potential benefits of these combinations, increasing demand. Furthermore, regulatory support has facilitated the development and approval of these innovative therapies, addressing the rising incidence of pancreatic cancer and the need for more effective treatment options.

Diagnostic Technology Insights

Genomic testing led the market and accounted for a share of 40.8% in 2024. Genomic testing has proven essential for personalized treatment approaches in pancreatic cancer, identifying actionable mutations that lead to better patient outcomes; studies showed 100% of patients had detectable alterations. Nearly one-third of advanced patients had their treatment plans modified based on genomic findings. Increased regulatory support and funding, along with rapid genomic testing technologies, have enhanced early detection and intervention for this aggressive disease.

To learn more about this report, Download Free Sample Report

Liquid biopsy is projected to grow at the fastest CAGR of 20.3% over the forecast period. Liquid biopsies offer a minimally invasive method for early pancreatic cancer detection, analyzing ctDNA and CTCs to improve outcomes. They allow real-time monitoring of tumor dynamics and characterization of heterogeneity, informing personalized therapies. Increasing regulatory recognition, such as from the NCCN, and ongoing research have improved test sensitivity and specificity. This advancement enhances liquid biopsies’ reliability and drives their adoption in clinical settings for managing pancreatic cancer.

Regional Insights

North America dominated the global pancreatic cancer precision medicine market with a revenue share of 42.9% in 2024, propelled by high incidence rates requiring effective treatments. Substantial research and development investments in genetic profiling and targeted therapies further drive market expansion. Supportive regulatory frameworks facilitate the approval and adoption of innovative precision medicine treatments, enhancing market growth and patient outcomes.

To learn more about this report, Download Free Sample Report

U.S. Pancreatic Cancer Precision Medicine Market Trends

The pancreatic cancer precision medicine industry in the U.S. dominated the North America region with a revenue share of 81.4% in 2024. The country is experiencing rising pancreatic cancer cases. Advances in genomic testing and liquid biopsies improve early detection and treatment personalization. Increased awareness of precision medicine among healthcare providers and patients enhances its adoption, leading to better patient management and therapeutic strategies.

Europe Pancreatic Cancer Precision Medicine Market Trends

Europe pancreatic cancer precision medicine industry held substantial market share in 2024, driven by rising pancreatic cancer prevalence necessitating enhanced diagnostic and therapeutic strategies. Collaborative research initiatives between academic institutions and pharmaceutical firms foster innovation in precision medicine. Supportive regulatory environments stimulate the development and implementation of precision therapies across the continent.

The pancreatic cancer precision medicine market in Germany is expected to grow in the forecast period, propelled by high pancreatic cancer incidence, accounting for approximately 3% of all cancers annually. Germany’s advanced healthcare system facilitates integrating precision medicine into clinical practice. Significant funding for cancer research enhances the development of tailored innovative therapies for pancreatic cancer patients.

Asia Pacific Pancreatic Cancer Precision Medicine Market Trends

Asia Pacific pancreatic cancer precision medicine industry is expected to register the fastest CAGR of 6.1% in the forecast period. The region is experiencing lifestyle-related risk factors increasing pancreatic cancer cases. Advancements in healthcare infrastructure and diagnostics facilitate precision medicine adoption. National health programs focusing on cancer prevention and treatment further boost market growth and enhance regional access to care.

The pancreatic cancer precision medicine market in Japan dominated the Asia Pacific region in 2024. In 2023, approximately 34,000 new cases were reported, underscoring the disease burden. Substantial investments in cancer research have promoted advancements in precision therapies tailored to individual patient profiles. Furthermore, supportive regulatory environments have fostered the development and approval of novel treatments, substantially enhancing patient access to these innovative medical interventions by 2025.

Key Pancreatic Cancer Precision Medicine Company Insights

Some key companies operating in the market include AstraZeneca; Pfizer Inc.; Novartis AG; Amgen Inc.; F. Hoffmann-La Roche Ltd; and Bayer AG; among others. Strategic collaborations among key stakeholders drive market growth through targeted therapies, immunotherapies, and diagnostic innovations such as liquid biopsies.

• Bayer AG actively participates in the pancreatic cancer precision medicine market, developing targeted therapies and immunotherapies. Their research focuses on personalized treatments to enhance patient outcomes and address unmet medical needs in pancreatic cancer care.

• Teva Pharmaceutical Industries Ltd contributes to the pancreatic cancer precision medicine industry through investment in advanced therapy research and development. Efforts include developing innovative drugs and treatment options to improve pancreatic cancer treatment effectiveness and precision.

Recent Developments

• In September 2024, Pfizer announced that its Phase 2 study of ponsegromab in the U.S. met primary endpoints, showing significant improvements in body weight and quality of life for cancer cachexia patients.

• In August 2024, Foundation Medicine (U.S.) collaborated with Merus to develop an RNA platform as a companion diagnostic for zenocutuzumab, aimed at treating NRG1 fusion-driven tumors.

• In March 2024, Bayer AG and Thermo Fisher Scientific partnered to develop NGS-based companion diagnostics, enhancing patient access to precision cancer therapies through decentralized genomic testing and rapid results.

• In March 2024, Bayer AG and Aignostics GmbH collaborated on AI-powered precision oncology, developing novel target identification platforms and algorithms to accelerate clinical development and improve patient selection in trials.

• In January 2024, Novartis AG presented Phase III NETTER-2 trial data, showing Lutathera significantly reduced disease progression or death risk by 72% as first-line treatment for advanced GEP-NETs.

Global Pancreatic Cancer Precision Medicine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global pancreatic cancer precision medicine market report based on therapeutic approach, diagnostic technology, and region:

To learn more about this report, Download Free Sample Report

• Therapeutic Approach Outlook (Revenue, USD Million, 2018 - 2030)

  • Targeted Therapy

    • PARP Inhibitors

    • Monoclonal Antibodies

    • Small Molecule Inhibitors - EGFR Inhibitors, KRAS Inhibitors

  • Immunotherapy

    • Immune Checkpoint Inhibitors - PD-1 Inhibitors, PD-L1 Inhibitors

    • Cancer Vaccines - GVAX, Algenpantucel-L

    • Adoptive T-Cell Therapies - CAR-T therapies

  • Chemotherapy-Precision Combinations

  • Other Therapeutic Approaches

• Diagnostic Technology Outlook (Revenue, USD Million, 2018 - 2030)

  • Genomic Testing

  • Molecular Diagnostics

  • Liquid Biopsy

  • Biomarker-based Companion Diagnostics

  • Others (Immunohistochemistry (IHC), Proteomics, Mass Spectrometry)

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait